Peetz Christopher 4

What Happened
Christopher Peetz, CEO of Mirum Pharmaceuticals, reported same‑day option exercises and open‑market sales on June 1, 2026. He exercised two derivative transactions of 30,000 shares each (one recorded as acquired at $2.94 per share for $88,080; the other recorded as a derivative disposal at $0). He also sold a total of 30,000 shares in multiple lots that day, generating aggregate proceeds of approximately $2,875,103 (individual weighted average sale prices ranged from ~$94.64 to ~$99.66 per lot).

Key Details

• Transaction date: June 1, 2026; Form filed June 2, 2026 (timely filing).
• Sales: 30,000 shares sold across six open‑market transactions (shares per lot: 2,602; 16,595; 6,926; 1,973; 1,021; 883). Reported proceeds ≈ $2,875,103. Weighted average prices per reported lot: $94.64, $95.34, $96.15, $97.56, $98.20, $99.66 (overall sale prices spanned roughly $93.90–$99.79 per share).
• Exercises/conversions (derivative): two 30,000‑share transactions — one "Acquired" at $2.94 (cost $88,080); one reported as "Disposed" at $0 (derivative). Filing notes the related stock option is fully vested.
• Plan/footnotes: Sales occurred pursuant to a Rule 10b5‑1 trading plan adopted March 2, 2026 (footnote F1). Additional footnotes provide the weighted average and price ranges for each sale lot.
• Shares owned after transaction: not specified in the provided filing details.

Context

• The combination of option exercises and same‑day sales is common for executives when exercising vested options and selling shares to cover exercise costs, tax withholding, or rebalancing. The filing shows an option exercise plus concurrent open‑market sales, and one exercise reported with no cash proceeds (often used to indicate net settlement or immediate disposition).
• Sales made under a prearranged 10b5‑1 plan are generally considered routine and planned in advance; they do not necessarily indicate a change in the insider’s long‑term view.